<DOC>
	<DOCNO>NCT02612077</DOCNO>
	<brief_summary>This longitudinal , multicenter , prospective , pharmacoepidemiological study evaluate progression free survival ( PFS ) real-life set participant metastatic colorectal cancer ( mCRC ) start chemotherapy combine bevacizumab .</brief_summary>
	<brief_title>Observation Patients With Metastatic Colorectal Cancer Starting Chemotherapy Combined With Bevacizumab ( Avastin )</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Having colon rectal metastatic adenocarcinoma , physician decide inclusion visit start treatment bevacizumab combine 1st , 2nd 3rd line chemotherapy Having receive oral write information survey object his/her data computerize Participating clinical trial assess anticancer treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>